C4 Therapeutics Shares Cemsidomide Biomarker Data at Myeloma Meeting
New trial data show cemsidomide drives robust T-cell activation in relapsed multiple myeloma patients, highlighting its dual mechanism of action.
C4 Therapeutics presented updated biomarker findings from two clinical trials of cemsidomide at the 23rd International Myeloma Society Annual Meeting, offering fresh insight into how the experimental therapy targets relapsed or refractory multiple myeloma.
Data from the Phase 1 trial combining cemsidomide with dexamethasone revealed robust T-cell activation, a finding the company described as central to the drug's dual mechanism of action. The results suggest cemsidomide does not merely degrade cancer-related proteins but also engages the immune system in fighting the disease.
Read more KB Home Opens City Vista Paired Homes in Escondido, CA →
Additional biomarker data were drawn from a Phase 1b trial pairing cemsidomide with elranatamab, the bispecific antibody marketed as ELREXFIO by Pfizer. Combining a targeted protein degrader with a bispecific antibody represents an emerging strategy in hematologic oncology, and the immunomodulatory signals observed may help explain early efficacy signals seen in heavily pretreated patient populations.
Multiple myeloma remains difficult to treat after multiple prior lines of therapy, and resistance to standard agents including immunomodulatory drugs and proteasome inhibitors is a persistent clinical challenge. Cemsidomide's ability to activate T cells alongside its targeted degradation activity could differentiate it from older agents in the same class, though larger randomized studies would be required to confirm clinical benefit.
Continue reading at GlobeNewswire - Industry News on Financial Services.
